[Assessment of schistosomiasis prevalence among children 5 to 14 years old after several years of mass drug administration in the Senegal River basin].

Introduction: The advent of Diama and Manantali dams in the eighties has altered the schistosomiasis profile in the Senegal River Basin, with the appearance of an intestinal form in the Delta and a high prevalence of the urinary form in all ecological areas of the basin. Methods: The present study was mainly designed to re-evaluate the prevalence of schistosomiasis after many years of mass drug administration with praziquantel 600 mg allowing analysis of the pertinence of World Health Organisation guidelines in terms of dosing frequency, particularly in the Senegal River Basin. Stools and urine from 1,215 public school children from 24 villagesidentified in three ecological areas of the Senegal River Basin (Delta, valley, upper basin), were examined.

Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania.

Background: In 2006, the Mauritanian Ministry of Health adopted a new therapeutic strategy based on the systematic use of artemisinin-based combination therapy (ACT), artesunate-amodiaquine and artemether-lumefantrine, for the first- and second-line treatment of uncomplicated malaria, respectively, regardless of Plasmodium spp. In the Saharan zone of the country, recent studies have shown that Plasmodium vivax largely predominates over Plasmodium falciparum. Anti-malarial drug response of P.

Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania.

Background: A regular evaluation of therapeutic efficacy in sentinel sites and a system of surveillance are required to establish treatment guidelines and adapt national anti-malarial drug policy to the rapidly changing epidemiology of drug-resistant malaria. The current anti-malarial treatment guideline in Mauritania, officially recommended since 2006, is based on artemisinin-based combination therapy. The aim of the present study was to evaluate clinical efficacy and tolerance of artesunate-amodiaquine, the first-line treatment for acute uncomplicated malaria, in Mauritanian paediatric and adult patients to validate its continued use in the country.